ClinicalTrials.gg
TerminatedNCT05565092PHOENIXUpdated Jan 13, 2025Results posted

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

A Phase 2 interventional study of ALXN1820 in Sickle Cell Disease (SCD), sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to terminate program.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
517th of 559
2 · median 31
Started
2023
with 23 others
Phase 2
161 of 733
23 open now
Registered
604th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 517th largest by enrollment of the 559 interventional ones that give a count, is one of 24 that started in 2023, is one of 161 in phase 2, and was the 604th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of ALXN1820 SC (subcutaneous) in participants with SCD (Sickle Cell Disease).

03

Conditions studied

  • Sickle Cell Disease (SCD)

Browse trials for

Keywords

  • Sickle Cell Disease
  • ALXN1820
  • SCD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of SCD (HbSS, or HbSβ0-thalassemia).
  • Body weight ≥ 40 kg (inclusive) at Screening.
  • Must follow protocol-specified guidance while on treatment and for up to 6 months after last dose.
  • between 5.5 and 10 g/dL at Screening
  • Have had 1 to 10 VOCs in the past 12 months.
  • Patients receiving hydroxyurea must have been on a stable dose for ≥ 3 months prior to providing , with no anticipated need for dose adjustment during the study.
  • Patients will be vaccinated with MCV4 and serogroup B meningococcal vaccinations at least 14 days before dosing, if not already vaccinated within 3 years before the first dose.
  • Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae vaccination are up to date according to current national/local vaccination guidelines for patients with SCD.

Exclusion criteria

Exclusion Criteria:

  • Planned initiation, termination, or dose alteration of hydroxyurea during the study.
  • Receiving Voxelotor (OXBRYTA) or crizanlizumab (ADAKVEO) within 60 days of providing .
  • Receiving treatment with recombinant human erythropoetins (eg, epoetin alfa).
  • Treated with complement inhibitors within 6 months prior to the first dose.
  • Patients who are on chronic transfusion or receive a transfusion within 60 days of first dose.
  • Any significant disease or disorder which, in the opinion of the Investigator, may put the participant at risk.
  • (positive hepatitis surface antigen [HBsAg] or positive core antibody (anti-HBc) with negative surface antibody [anti-HBs]) or viral infection (hepatitis C virus [HCV] antibody positive, except for patients with documented successful treatment and documented sustained virologic response) at Screening.
  • Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing.
  • Participation (ie, last protocol-required study visit) in a clinical study within 90 days or 5 half-lives of the agent, whichever is longer, before initiation of dosing on Day 1.
  • Participation in more than 1 clinical study of a monoclonal antibody (mAb), or participation in a clinical study of a mAb within the 6 months or 5 half-lives of the mAb, whichever is longer, prior to Screening, during which the participant was exposed to the active study drug.
  • Severe renal impairment (estimated [eGFR] \< 30 mL/min/1.73 m2 ) or on chronic dialysis.
  • History of allergy or to of ALXN1820 (eg, polysorbate 80).
  • History of complement deficiency.
  • History of N meningitidis, S pneumoniae, or H influenzae infection.
  • History of with the exception of a nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence within 5 years.
  • Participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    ALXN1820 300 mg once weekly

    Participants will receive 300 milligrams (mg) once weekly (QW).

    Drug: ALXN1820

  • Experimental
    ALXN1820 600 mg once every 4 weeks

    Participants will receive 600 mg once every 4 weeks (Q4W).

    Drug: ALXN1820

  • Experimental
    ALXN1820 300 mg once every 2 weeks (Optional cohort)

    Participants will receive 300 mg once every 2 weeks (Q2W).

    Drug: ALXN1820

Interventions

  • ALXN1820 will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events

    Time frame: Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

Secondary outcomes

  1. Pharmacokinetics: Serum ALXN1820 Concentration

    Time frame: Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

  2. Change From Baseline in Serum Concentration of Total and Free Properdin Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

    Time frame: Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

  3. Change From Baseline Complement Alternative Pathway Activity Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

    Time frame: Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

  4. Change From Baseline in Complement Biomarkers Through Week 12 (Cohorts 1 and 2)

    Time frame: Baseline, Week 12

  5. Change From Baseline in Hemoglobin Level at Week 12 (Cohorts 1 and 2)

    Time frame: Baseline, Week 12

  6. Change From Baseline in Hemolysis Markers at Week 12 (Cohorts 1 and 2)

    Time frame: Baseline, Week 12

  7. Change From Baseline in Hemopexin at Week 12 (Cohorts 1 and 2)

    Time frame: Baseline, Week 12

  8. Number of Participants With Antidrug Antibodies to ALXN1820

    Time frame: Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

07

Results

Posted Jan 13, 2025
Limitations and caveats
Per Sponsor decision, the study was terminated. Only 2 participants were enrolled. Due to concerns regarding participant confidentiality, no data are reported.

Participant flow

Per Sponsor decision, the study was terminated. Only 2 participants were enrolled. Due to concerns regarding participant confidentiality, no data are reported.

Participant flow — Overall Study
MilestoneALXN1820 300 mg QWALXN1820 600 mg Q4WALXN1820 300 mg Q2W (Optional Cohort)
Started000
Completed000
Not completed000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
Time frame:
Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

No measurements were reported for this outcome.

SecondaryPharmacokinetics: Serum ALXN1820 Concentration
Time frame:
Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Serum Concentration of Total and Free Properdin Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)
Time frame:
Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

No measurements were reported for this outcome.

SecondaryChange From Baseline Complement Alternative Pathway Activity Through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)
Time frame:
Baseline through Day 211 (Cohorts 1 and 2) and Day 169 (Optional Cohort 3)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Complement Biomarkers Through Week 12 (Cohorts 1 and 2)
Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemoglobin Level at Week 12 (Cohorts 1 and 2)
Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemolysis Markers at Week 12 (Cohorts 1 and 2)
Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemopexin at Week 12 (Cohorts 1 and 2)
Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

SecondaryNumber of Participants With Antidrug Antibodies to ALXN1820
Time frame:
Baseline through Day 211 (Cohorts 1 and 2) and through Day 169 (Optional Cohort 3)

No measurements were reported for this outcome.

Adverse events

Collected over Per Sponsor decision, the study was terminated. Only 2 participants were enrolled. Due to concerns regarding participant confidentiality, no data are reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALXN1820 300 mg QW———
ALXN1820 600 mg Q4W———
ALXN1820 300 mg Q2W (Optional Cohort)———

Baseline characteristics

Per Sponsor decision, the study was terminated. Only 2 participants were enrolled. Due to concerns regarding participant confidentiality, no data are reported.

Age, Categorical
Age, CategoricalALXN1820 300 mg QWALXN1820 600 mg Q4WALXN1820 300 mg Q2W (Optional Cohort)Total
<=18 years————
Between 18 and 65 years————
>=65 years————
Sex: Female, Male
Sex: Female, MaleALXN1820 300 mg QWALXN1820 600 mg Q4WALXN1820 300 mg Q2W (Optional Cohort)Total
Female————
Male————
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)ALXN1820 300 mg QWALXN1820 600 mg Q4WALXN1820 300 mg Q2W (Optional Cohort)Total
Hispanic or Latino————
Not Hispanic or Latino————
Unknown or Not Reported————
08

Study locations

2 sites
  • Research Site
    Hollywood, Florida 33023, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jan 2024, 10 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Oct 4, 2022
StartActual
Feb 22, 2023
Primary completionActual
Jan 9, 2024
CompletionActual
Jan 9, 2024
Results first posted
Jan 13, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05565092
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Feb 22, 2023
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Results posted
Jan 13, 2025
Last update
Jan 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tarperprumig

Start the discussion